Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 Patients
Announces Next Steps in Development Program for Lead Product Candidate
Ended Quarter with $21.9 million in Cash and Cash Equivalents
CHARLOTTESVILLE, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”) today reported financial results for the three and nine months ended September 30, 2020 and provided certain updates on its development program for its lead product candidate, trans sodium crocetinate (“TSC”), which is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.
Third quarter results, recent developments, and anticipated next steps in the TSC development program include:
Third Quarter Results & Recent Developments
| • | Strengthened leadership team with additions and appointments to key management positions, including pharmaceutical industry veterans Jane Hollingsworth, as director, Robert Cobuzzi, Ph.D., as president and chief executive officer, and Chris Galloway, M.D., as chief medical officer, as well as Bill Elder, J.D., as general counsel. | |
| • | Ended quarter with $21.9 million in cash and cash equivalents. | |
| • | Announced dosing of first two patients in Phase 1b clinical trial evaluating TSC in hospitalized COVID-19 patients (the “100-303 COVID Trial”) with primary endpoint of evaluating safety and tolerability of TSC administered every six hours for up to 15 days, a more frequent dosing regimen than has been used in the Company’s previous clinical studies. | |
| • | As of November 11, 2020, patient enrollment continues, and no dose-limiting toxicities have been observed. |
Near-Term Strategy
| • | Ongoing review of existing TSC development program with plans to modify the program and accomplish two principal strategic objectives: | |||
| • | Optimize the clinical dose and dosing frequency for TSC. | |||
| • | Evaluate TSC in clinical models designed to establish proof of concept for improvement in oxygenation following administration of TSC. | |||
| • | Designing and initiating additional studies in effort to accomplish strategic objectives: | |||
| • | Evaluating possibility of expanding 100-303 COVID Trial to include additional doses administered on the same regimen, assuming successful and timely completion of currently planned doses and final regulatory approval of pending protocol amendment to effect change. | |||
| • | Designing additional clinical studies intended to evaluate (i) the effects of TSC using short-term experimental models of oxygenation with the expected primary objective of establishing proof of concept for improvement of tissue oxygen levels and certain other clinical parameters and (ii) depending on whether or not the Company decides to implement the expansion of the 100-303 COVID Trial, additional doses of TSC on a more frequent dosing regimen. | |||
| • | Diffusion expects to fully fund these studies with cash-on-hand. | |||
| • | Diffusion intends to provide certain additional details regarding the design of these new studies in January 2021 and to initiate the studies during the first quarter of 2021. The Company also now expects the 100-303 COVID Trial, whether or not the Company decides to implement the expansion described above, to be completed with topline data available by the end of first quarter of 2021. | |||
Other Events
| • | Diffusion currently intends to participate in two virtual, biopharmaceutical and biotechnology industry conferences in mid-January 2021 – Biotech Showcase and the H.C. Wainwright 2021 Bioconnect Conference – and to provide its next update regarding its development program for TSC at that time. | |
| • | Launched new website design at www.diffusionpharma.com. |
“Hypoxia can be a serious complication of a multitude of acute and chronic disease processes in patients of all ages and represents a continued area of unmet need that spans multiple therapeutic areas. I am excited about our development plans, which we believe will clarify TSC’s mechanism of action in controlled human studies of oxygenation. We intend to use these data to inform and evaluate our further development opportunities for TSC, as well as potential patient populations and indications,” said Chris Galloway, M.D., Chief Medical Officer of Diffusion.
“Diffusion has experienced a lot of changes over the past few months. While we continue to refine our vision for the Company, we are pleased with the progress we made during the third quarter and we are excited to begin implementing our plans during the coming months,” said Robert Cobuzzi, Ph.D., Chief Executive Officer of Diffusion. “We believe our near-term strategy will significantly improve the probability of development success for TSC by providing the opportunity to optimize dosing and obtain a clear clinical signal supporting the potential value of TSC’s mechanism of action across a broad range of conditions in which hypoxia remains a significant obstacle to effective treatment.”
Third Quarter Financial Results
Research and development (“R&D”) expenses were $3.1 million during the third quarter of 2020, compared with $1.7 million during the third quarter of 2019. A significant portion of the increase, $1.4 million, was attributable to expenses related to the initiation of the Company’s ongoing clinical trial evaluating TSC in COVID-19 patients. In addition, R&D expenses included $0.1 million related to winding down the Company’s Phase 2 stroke trial.
General and administrative (“G&A”) expenses were $2.1 million during the third quarter of 2020, compared with $1.3 million during the third quarter of 2019. The increase was primarily due to a $0.2 million increase in professional fees and a $0.6 million increase in salaries, wages and stock-based compensation expenses, including non-recurring expenses related to the retirement, resignation and separation of the Company’s former Chief Executive Officer in September 2020.
The Company recognized income tax benefits of $0.8 million and $0.2 million during the third quarters of 2020 and 2019, respectively. In both periods, the recognized benefit reflects the Company’s utilization of indefinite deferred tax liabilities as a source of income against indefinite lived portions of its deferred tax assets.
Diffusion had cash and cash equivalents of $21.9 million as of September 30, 2020, compared with $14.2 million as of December 31, 2019, and believes its cash and cash equivalents are sufficient to fund operating expenses and capital expenditures into the fourth quarter of 2022.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. The Company’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. For more information please visit us on the web at www.diffusionpharma.com.
Forward-Looking Statements
This press release includes express and implied forward-looking statements including, without limitation, statements regarding the Company’s ongoing clinical trials and development plans for its product candidates and the Company’s financial condition, liquidity, and capital resources. By their nature, forward-looking statements involve risks and uncertainties because they relate to and depend on, among other things, events, competitive dynamics, and industry change. The Company may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, as a result of certain risks and uncertainties, known and unknown, the Company’s actual results could differ materially from any intentions, beliefs, projections, outlook, analyses, or expectations expressed herein. Particular risk and uncertainties include, among other things, those related to: the Company’s ability to design, initiate, execute, and complete its ongoing and planned studies evaluating TSC; the Company’s ability to achieve its near-term strategic objectives, in the near-term or at all; the Company’s ability to obtain additional financing; the success and timing of the Company’s clinical trials and preclinical studies, including its ability to enroll subjects in such trials and studies at anticipated rates; the Company’s ability to develop and commercialize TSC or any other product candidate; the ongoing COVID-19 pandemic; general economic, political, business, industry, and market conditions, including the recent United States (“U.S.”) presidential election; and the other factors discussed under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”). Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule or regulation, the Company undertakes no obligation to update any such statements after the date hereof. Comparisons of current and any prior period results are not intended to express any ongoing or future trends or indications of future performance, unless explicitly expressed as such, and should only be viewed as historical data. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
Media Contact:
Jeffrey Freedman
RooneyPartners
(646) 432-0191
jfreedman@rooneyco.com
(Tables to follow)
| Diffusion Pharmaceuticals Inc. | ||||||
| Consolidated Balance Sheet | ||||||
| (unaudited) | ||||||
| September 30, 2020 | December 31, 2019 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 21,910,183 | $ | 14,177,349 | ||
| Prepaid expenses, deposits and other current assets | 766,932 | 472,464 | ||||
| Total current assets | 22,677,115 | 14,649,813 | ||||
| Property and equipment, net | 174,133 | 252,366 | ||||
| Intangible asset | 8,639,000 | 8,639,000 | ||||
| Right of use asset | 174,668 | 247,043 | ||||
| Other assets | 252,057 | 322,301 | ||||
| Total assets | $ | 31,916,973 | $ | 24,110,523 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 1,411,717 | $ | 1,251,412 | ||
| Accrued expenses and other current liabilities | 1,162,278 | 358,532 | ||||
| Current operating lease liability | 112,953 | 111,477 | ||||
| Total current liabilities | 2,686,948 | 1,721,421 | ||||
| Deferred income taxes | 443,893 | 2,119,274 | ||||
| Noncurrent operating lease liability | 61,715 | 135,566 | ||||
| Total liabilities | 3,192,556 | 3,976,261 | ||||
| Stockholders’ Equity: | ||||||
| Common stock, $0.001 par value: | ||||||
| 1,000,000,000 shares authorized; 64,015,441 and 33,480,365 issued and outstanding at September 30, 2020 and December 31, 2019, respectively | 64,016 | 33,481 | ||||
| Additional paid-in capital | 130,507,728 | 111,824,859 | ||||
| Accumulated deficit | (101,847,327 | ) | (91,724,078 | ) | ||
| Total stockholders' equity | 28,724,417 | 20,134,262 | ||||
| Total liabilities and stockholders' equity | $ | 31,916,973 | $ | 24,110,523 | ||
| Diffusion Pharmaceuticals Inc. | |||||||||||||||
| Consolidated Statement of Operations | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 3,137,553 | $ | 1,743,494 | $ | 6,845,203 | $ | 4,961,720 | |||||||
| General and administrative | 2,112,375 | 1,290,371 | 4,964,440 | 3,559,551 | |||||||||||
| Depreciation | 24,192 | 18,178 | 78,233 | 70,840 | |||||||||||
| Loss from operations | (5,274,120 | ) | (3,052,043 | ) | (11,887,876 | ) | (8,592,111 | ) | |||||||
| Other income: | |||||||||||||||
| Interest income | 29,233 | 21,991 | 89,246 | 59,596 | |||||||||||
| Loss from operations before income tax benefit | (5,244,887 | ) | (3,030,052 | ) | (11,798,630 | ) | (8,532,515 | ) | |||||||
| Income tax benefit | 805,676 | 225,960 | 1,675,381 | 485,216 | |||||||||||
| Net loss | $ | (4,439,211 | ) | $ | (2,804,092 | ) | $ | (10,123,249 | ) | $ | (8,047,299 | ) | |||
| Deemed dividend arising from warrant exchange | — | — | (1,950,378 | ) | — | ||||||||||
| Net loss attributable to common stockholders | $ | (4,439,211 | ) | $ | (2,804,092 | ) | $ | (12,073,627 | ) | $ | (8,047,299 | ) | |||
| Per share information: | |||||||||||||||
| Net loss per share of common stock, basic and diluted | $ | (0.07 | ) | $ | (0.60 | ) | $ | (0.24 | ) | $ | (2.01 | ) | |||
| Weighted average shares outstanding, basic and diluted | 64,011,342 | 4,693,290 | 50,216,239 | 4,005,919 | |||||||||||